242 related articles for article (PubMed ID: 15118759)
1. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
Siders WM; Halloran PJ; Fenton RG
Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene.
Sieger S; Jiang S; Kleinschmidt J; Eskerski H; Schönsiegel F; Altmann A; Mier W; Haberkorn U
Cancer Gene Ther; 2004 Jan; 11(1):41-51. PubMed ID: 14681725
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors.
Jiang S; Altmann A; Grimm D; Kleinschmidt JA; Schilling T; Germann C; Haberkorn U
Cancer Gene Ther; 2001 Jul; 8(7):469-72. PubMed ID: 11498767
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H
Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481
[TBL] [Abstract][Full Text] [Related]
7. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
8. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K
Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.
Esandi MC; van Someren GD; Vincent AJ; van Bekkum DW; Valerio D; Bout A; Noteboom JL
Gene Ther; 1997 Apr; 4(4):280-7. PubMed ID: 9176512
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.
Kanai F; Shiratori Y; Yoshida Y; Wakimoto H; Hamada H; Kanegae Y; Saito I; Nakabayashi H; Tamaoki T; Tanaka T; Lan KH; Kato N; Shiina S; Omata M
Hepatology; 1996 Jun; 23(6):1359-68. PubMed ID: 8675152
[TBL] [Abstract][Full Text] [Related]
11. The effect of HSV-tk/GCV on hepatic specific damage driven by murine ALB promoter/enhancer.
Zhang Y; Huang SZ; Zeng YT
Yi Chuan Xue Bao; 2004 Oct; 31(10):1053-60. PubMed ID: 15552038
[TBL] [Abstract][Full Text] [Related]
12. Suicide gene therapy using keratin 19 enhancer and promoter in malignant mesothelioma cells.
Ishiwata N; Inase N; Fujie T; Tamaoka M; Yoshizawa Y
Anticancer Res; 2003; 23(2B):1405-9. PubMed ID: 12820402
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
Vile R; Miller N; Chernajovsky Y; Hart I
Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
[TBL] [Abstract][Full Text] [Related]
14. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
15. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.
Adachi Y; Reynolds PN; Yamamoto M; Grizzle WE; Overturf K; Matsubara S; Muramatsu T; Curiel DT
Cancer Res; 2000 Aug; 60(16):4305-10. PubMed ID: 10969765
[TBL] [Abstract][Full Text] [Related]
16. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.
Vile RG; Nelson JA; Castleden S; Chong H; Hart IR
Cancer Res; 1994 Dec; 54(23):6228-34. PubMed ID: 7954471
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis.
Painter RG; Lanson NA; Jin Z; Park F; Wang G
Cancer Sci; 2005 Sep; 96(9):607-13. PubMed ID: 16128746
[TBL] [Abstract][Full Text] [Related]
18. Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene.
Pastorakova A; Hlubinova K; Jakubikova J; Altaner C
Neoplasma; 2006; 53(5):353-62. PubMed ID: 17013529
[TBL] [Abstract][Full Text] [Related]
19. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors.
Veldwijk MR; Berlinghoff S; Laufs S; Hengge UR; Zeller WJ; Wenz F; Fruehauf S
Cancer Gene Ther; 2004 Aug; 11(8):577-84. PubMed ID: 15280909
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
Siders WM; Halloran PJ; Fenton RG
Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
